Results 171 to 180 of about 126,252 (309)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Generalization of placebo pain relief

, 2019
Lea Kampermann, Christian Büchel
openalex   +1 more source

A dose of doubt: a qualitative study on placebo regulations. [PDF]

Front Med (Lausanne)
Richard M, Ganz M, Elger BS, Gaab J.
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

Investigating Placebos and Controls Used in Large Language Model-Based Chatbot Intervention Trials: Protocol for a Methodological Review. [PDF]

JMIR Res Protoc
Druart L, Faria V, Annoni M, Torous J, Pontén M, Blease C.   +5 more
europepmc   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

The Efficacy of Aromatherapy on Pain and Anxiety During Needle-Related Procedures in Adults: A Systematic Review and Meta-Analysis [Letter]. [PDF]

J Pain Res
Wang Z, Ke S, Liu Q.
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Efeito do enxágue bucal com carboidrato sobre o desempenho em exercício realizado em condição de fadiga mental: um estudo duplo-cego, cruzado e controlado por placebo [PDF]

, 2019
Renata Gonçalves Silva
openalex   +1 more source

Transitioning from deceptive to nondeceptive placebo treatment to reduce pathological skin-picking. [PDF]

Discov Ment Health
Schienle A, Wilhelm J, Tanzmeister S.
europepmc   +1 more source